We then assessed whether the presence of CH and CH-PD was associated with the need for G-CSF support during first-line systemic therapy, specifically the proportion of platinum- or irinotecan-containing cycles that required G-CSF support. The gene discussed is CSF3; the disease is cyclic hematopoiesis.